Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal

HRS-9821 is being developed to treat chronic obstructive pulmonary disease (COPD), while the other projects are in early development across areas such as oncology, respiratory, immunology, and inflammation.